ESMO 2025

ESMO 2025
October 17-21, 2025
Berlin, Germany

European Society for Medical Oncology.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (5)

    Long-term safety profile of sacituzumab govitecan vs docetaxel in patients with metastatic non–small cell lung cancer from EVOKE-01

    • Author(s): Felip, E
    • trodelvy
    • Oncology
    • Poster

    Domvanalimab, zimberelimab, and FOLFOX in first-line advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma: 26-month update from EDGE-Gastric, Arm A1

    • Author(s): Rha, SY
    • domvanalimab
    • zimberelimab
    • Oncology
    • Oral

    Phase 2 study of sacituzumab govitecan, domvanalimab, and zimberelimab in metastatic non–small cell lung cancer: VELOCITY-Lung Substudy-01

    • Author(s): Ahn, M
    • trodelvy
    • domvanalimab
    • zimberelimab
    • Oncology
    • Poster

    Patient-reported outcomes with sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in patients with previously untreated PD-L1+ mTNBC in the phase 3 ASCENT-04/KEYNOTE-D19 study

    • Author(s): De Azambuja, A
    • trodelvy
    • Oncology
    • Oral

    Primary results from ASCENT-03: A randomized Phase 3 study of sacituzumab govitecan vs chemotherapy in patients with previously untreated advanced triple-negative breast cancer who are not candidates for PD-(L)1 inhibitors

    • Author(s): Cortes, J
    • trodelvy
    • Oncology
    • Oral